计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| N413659-2mg |
2mg |
现货 ![]() |
| |
| N413659-5mg |
5mg |
期货 ![]() |
| |
| N413659-10mg |
10mg |
现货 ![]() |
| |
| N413659-25mg |
25mg |
现货 ![]() |
| |
| N413659-50mg |
50mg |
现货 ![]() |
| |
| N413659-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | 2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | NE 52-QQ57 |
| 生化机理 | NE 52-QQ57 是一种选择性口服 G 蛋白偶联受体 4 (GPR4) 拮抗剂,IC50 为 0.07 μM。NE 52-QQ57 能有效阻断 GPR4 介导的 cAMP 积累,在 HEK293 细胞中的 IC50 为 26.8 nM。NE 52-QQ57 与 GPR4 的拮抗作用可显著抑制 AGE 诱导的几种关键炎症细胞因子和信号分子的表达增加,包括肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-1β、IL-6、诱导型一氧化氮合酶(iNOS)、一氧化氮(NO)、环氧化酶 2(COX2)和前列腺素 E2(PGE2)。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 拮抗剂 |
| 作用机制 | GPR4 拮抗剂 |
| 产品介绍 |
Information NE 52-QQ57 is a selective, and orally available antagonist ofG-protein coupled receptor 4 (GPR4)with IC50 of 0.07 μM. NE 52-QQ57 effectively blocks GPR4-mediated cAMP accumulation with IC50 of 26.8 nM in HEK293 cells. The antagonism of GPR4 with NE 52-QQ57 significantly inhibits the AGE-induced increased expression of several key inflammatory cytokines and signaling molecules, includingtumor necrosis factor-α (TNF-α),interleukin (IL)-1β,IL-6,inducible nitric Targets TNF-α ; IL-1β ; IL-6 ; iNOS ; NO 33706,; |
| ALogP | 3.242 |
|---|---|
| HBD Count | 1 |
| Rotatable Bond | 5 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504771940 |
|---|---|
| 分子类型 | 小分子 |
| IUPAC Name | 2-[4-[(2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl]phenyl]-5-piperidin-4-yl-1,3,4-oxadiazole |
| INCHI | InChI=1S/C24H28N6O/c1-4-21-20(22-26-15(2)13-16(3)30(22)29-21)14-17-5-7-18(8-6-17)23-27-28-24(31-23)19-9-11-25-12-10-19/h5-8,13,19,25H,4,9-12,14H2,1-3H3 |
| InChi Key | HXPQWNPLNIEJOW-UHFFFAOYSA-N |
| Canonical SMILES | CCC1=NN2C(=CC(=NC2=C1CC3=CC=C(C=C3)C4=NN=C(O4)C5CCNCC5)C)C |
| Isomeric SMILES | CCC1=NN2C(=CC(=NC2=C1CC3=CC=C(C=C3)C4=NN=C(O4)C5CCNCC5)C)C |
| PubChem CID | 68379135 |
| MeSH Entry Terms | 2-(4-((2-Ethyl-5,7-dimethylpyrazolo(1,5-a)pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole;NE-52-qq57 |
| 分子量 | 416.52 |
| 溶解性 | Solubility (25°C) In vitro Ethanol: 45 mg/mL (108.03 mM); DMSO: 20 mg/mL (48.01 mM); Water: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 20 |
| DMSO(mM) Max Solubility | 48.0169019494862 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 416.500 g/mol |
| XLogP3 | 3.500 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 416.232 Da |
| 单同位素质量Monoisotopic Mass | 416.232 Da |
| 拓扑极表面积Topological Polar Surface Area | 81.100 Ų |
| 重原子数Heavy Atom Count | 31 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 578.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| Purity(HPLC) | 98-100(%) |
|---|---|
| NMR Spectrum 1H | Conforms to Structure |
| 1. Velcicky J, Miltz W, Oberhauser B, Orain D, Vaupel A, Weigand K, Dawson King J, Littlewood-Evans A, Nash M, Feifel R et al.. (2017) Development of Selective, Orally Active GPR4 Antagonists with Modulatory Effects on Nociception, Inflammation, and Angiogenesis.. J Med Chem, 60 (9): (3672-3683). [PMID:28445047] |
| 2. Miltz W, Velcicky J, Dawson J, Littlewood-Evans A, Ludwig MG, Seuwen K, Feifel R, Oberhauser B, Meyer A, Gabriel D et al.. (2017) Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis.. Bioorg Med Chem, 25 (16): (4512-4525). [PMID:28689977] |